GlassScriptPhysician profile
Nishith Amin
NPI 1336136860
$3,287.06
in general payments reported to CMS, 2019-2025
35 companies · $642 in 2025
The $642 reported for 2025 was less than what a typical Interventional Cardiology provider received nationally (typical 2025 total: $1,092).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $875 · 2020: $116 · 2021: $142 · 2022: $309 · 2023: $646 · 2024: $557 · 2025: $642.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,824 · Education: $21.70.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,823.69 |
| Education | $21.70 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $333.74 | 2019-2024 | |
| Amgen INC. | $321.00 | 2019-2025 | Repatha, Repatha, Otezla |
| Astrazeneca Pharmaceuticals LP | $228.70 | 2019-2025 | Farxiga, Breztri, Brilinta |
| Abiomed | $218.11 | 2019-2023 | Impella |
| Cardiovascular Systems INC. | $217.47 | 2019 | |
| Merck Sharp & Dohme LLC | $214.31 | 2023-2025 | Verquvo, Winrevair, Capvaxive |
| Medtronic, INC. | $209.79 | 2022-2025 | Micra, Evera Mri Xt Dr Surescan, Mycarelink |
| Edwards Lifesciences Corporation | $166.45 | 2019-2025 | |
| Novo Nordisk INC | $164.60 | 2023-2025 | Rybelsus, Ozempic, Wegovy |
| Lilly USA, LLC | $145.57 | 2022-2024 | Jardiance |
| Biotronik INC. | $137.38 | 2019-2023 | Acticor 7 Vr-T Dx |
| Ekos Corporation | $134.61 | 2019 | |
| Inari Medical, INC. | $84.90 | 2019 | |
| Corcept Therapeutics | $77.47 | 2025 | Korlym |
| Teva Pharmaceuticals USA, INC. | $66.60 | 2023-2025 | Austedo Xr, Austedo Xr |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $54.68 | 2023-2024 | Jardiance |
| Pfizer INC. | $44.91 | 2019-2025 | |
| Inspire Medical Systems, INC. | $44.46 | 2024 | Inspire |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $43.43 | 2020-2023 | Lifevest |
| Kiniksa Pharmaceuticals, LTD. | $41.83 | 2023 | Arcalyst |
| Bayer Healthcare Pharmaceuticals INC. | $39.27 | 2025 | |
| Regeneron Healthcare Solutions, INC. | $37.18 | 2019 | |
| Lexicon Pharmaceuticals, INC. | $33.92 | 2023-2024 | Inpefa |
| Janssen Pharmaceuticals, INC | $28.45 | 2019-2020 | |
| E.R. Squibb & Sons, L.L.C. | $25.50 | 2022 | |
| Abbott Laboratories | $24.05 | 2022 | |
| Penumbra, INC. | $23.68 | 2020 | |
| Insulet Corporation | $23.35 | 2025 | Omnipod |
| Abbvie INC. | $22.33 | 2023 | Vraylar |
| Amarin Pharma, INC. | $15.66 | 2020 | |
| Collegium Pharmaceutical, INC. | $13.99 | 2023 | Xtampza |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $13.50 | 2024 | Xifaxan |
| Celonova Biosciences, INC. | $13.19 | 2019 | |
| Gilead Sciences, INC. | $11.98 | 2019 | |
| Boston Scientific Corporation | $11.00 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nishith Amin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.